Skip to search formSkip to main contentSkip to account menu

Smoothened Antagonist LDE225

Known as: LDE-225, LDE225, NVP-LDE225 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Biphenyl CompoundsPyridines
Smoothened Antagonist LDE225 Topical

Narrower (1)

sonidegib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma
Background Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and… 
Highly Cited
2016
Highly Cited
2016
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
Targeting the Hedgehog (Hh) pathway represents a potential leukaemia stem cell (LSC)-directed therapy which may compliment… 
Review
2016
Review
2016
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Highly Cited
2015
Highly Cited
2015
PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth
Cancer stem cells (CSCs) play major roles in cancer initiation, progression, and metastasis. It is evident from growing reports… 
Highly Cited
2013
Highly Cited
2013
NVP-LDE-225 (Erismodegib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128
Prostate cancer stem cells (CSCs) are defined by their extensive self-renewal, differentiation and tumor initiation properties… 
Highly Cited
2013
Highly Cited
2013
Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis
The JAK1/2 dual kinase inhibitor INC424 (ruxolitiniba, Jakafi¨) has been recently approved for the treatment of intermediate or… 
Highly Cited
2012
Highly Cited
2012
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer
The hedgehog pathway has been implicated in the formation and maintenance of a variety of malignancies, including ovarian cancer… 
Highly Cited
2012
Highly Cited
2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
The Hedgehog (Hh) pathway is required for cell-fate determination during the embryonic life, as well as cell growth and… 
Highly Cited
2010
Highly Cited
2010
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.
The blockade of aberrant hedgehog (Hh) signaling has shown promise for therapeutic intervention in cancer. A cell-based… 
2010
2010
A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors.
2500 Background: LDE225 is a potent and selective inhibitor of Smo, a key signaling protein in the hedgehog (Hh) pathway… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)